Login to Your Account



Positive Early Data Halting Herceptin Phase III Studies

By Randall Osborne


Wednesday, April 27, 2005
With off-label use of Herceptin already slowly growing for early stage breast cancer patients, Genentech Inc. said two Phase III trials in that population were stopped after an interim analysis showed the drug offered benefit. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription